Bread, you don't seem to understand one very important aspect of this: They are mainly producing, researching, distributing for OTHER companies. They have some own developments. But their main focus is not to develop their own drugs. It says so on their website. Clearly. They are mainly a pharma SERVICE company.
They produce/sell active ingredients (API), pallets, laboratory assets (like lab mice), all sorts of pharmaceutical stuff. They distribute drugs for other companies. They execute R&D for other companies. They produce generic drugs for the Chinese market and for other companies. Et cetera.
Fukangren is a company that (mostly) works in the background or in collaborations. At their core they are a service provider.
I honestly think that it's really very obvious.
- Forums
- ASX - By Stock
- AN1
- China deal..... Fukang Ren?
China deal..... Fukang Ren?, page-39
-
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online